Login / Signup

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.

Malaka AmeratungaIrene BranaPetri BonoSophie Postel-VinayRuth PlummerJohn AspegrenTimo KorjamoAmir SnapirJohann S de Bono
Published in: British journal of cancer (2020)
The clinical trial registration number is NCT03035591.
Keyphrases
  • clinical trial
  • open label
  • endothelial cells
  • phase ii
  • study protocol
  • phase iii
  • induced pluripotent stem cells
  • randomized controlled trial
  • phase ii study
  • squamous cell carcinoma